EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY-NC 4.0

Single-Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A DUE Phase 3 Trial

Fenling Fan, Stacy Davis, Claire Burbridge, Kelly Chin, Michael Friberg, Ekkehard Grünig, Melanie Hughes, Pavel Jansa, Jörg Linder, Jennifer Rafalski, Alvaro Agustin Rodriguez, Jason A Randall

Advances in Therapy · 2025

DOI: 10.1007/s12325-025-03159-x ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Fenling Fan und 11 weiteren Autor:innen. Beteiligte Einrichtung: First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Global Services, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study explored patient and clinician perspectives on a new fixed-dose combination of macitentan and tadalafil (M/T FDC) in a once-daily single tablet for treatment of pulmonary arterial hypertension (PAH). METHODS: Qualitative semi-structured interviews were conducted during the open-label period of the global, phase 3 A DUE clinical trial that evaluated M/T FDC. A subset of enrolled patients (N = 26) and site investigators (N = 18 clinicians) were interviewed. Patients received four tablets during double-blind treatment and could be in one of three arms (macitentan + placebo; tadalafil + placebo; M/T FDC + placebo) followed by M/T FDC (one tablet) during the open-label period. Patients and clinicians were asked to share their experience of pre-trial PAH medication, double-blind treatment, and open-label M/T FDC. Thematic analysis was conducted on blinded data. RESULTS: Patients preferred the M/T FDC tablet (open-label) over the four tablets during double-blind treatment. Patients were satisfied with M/T FDC, highlighting its positive impact on their psychological well-being, through reducing stress associated with managing multiple pills. All patients indicated that having a single, once-a-day pill for PAH was more convenient and associated with greater treatment adherence. Clinicians highlighted that their patients have a high daily pill burden for PAH and other comorbidities, and prefer treatments with an oral mode of administration that reduce the number of daily pills required. Clinicians felt that M/T FDC would be well received in clinical practice and potentially assist in implementing guideline-recommended combination treatment of PAH. CONCLUSIONS: In this qualitative analysis, all 26 patients and 18 clinicians provided positive feedback on M/T FDC treatment, which was consistent across countries. Reducing the number of pills needed to treat PAH, through use of single-tablet M/T FDC, is highly valued by patients and endorsed by clinicians, who both felt the single-tablet combination therapy could have a positive effect on patients' well-being and increase treatment adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsHypertension, PulmonaryPulmonary Arterial HypertensionPyrimidinesSulfonamidesTadalafilAdultAgedFemaleHumansMaleMiddle AgedAdaptive Clinical Trials as TopicClinical Trials, Phase III as TopicDouble-Blind MethodDrug CombinationsInterviews as TopicMulticenter Studies as TopicPatient SatisfactionPhosphodiesterase 5 InhibitorsQualitative ResearchRandomized Controlled Trials as TopicTablets

Stichwörter der Autor:innen

Clinician interviewFixed-dose combinationPatient interviewPatient perspectivePolypharmacyPulmonary arterial hypertensionTreatment adherence

Substanzen

Antihypertensive AgentsDrug CombinationsmacitentanPhosphodiesterase 5 InhibitorsPyrimidinesSulfonamidesTabletsTadalafilmacitentan-tadalafil

Autor:innen und Institutionen

  • First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Janssen Global Services, LLC, a Johnson & Johnson Company, Horsham, PA, USA.
  • Clinical Outcomes Solutions, Folkestone, UK.
  • UT Southwestern Medical Center, Dallas, TX, USA.
  • Janssen-Cilag Limited, a Johnson & Johnson Company, Clinical Science, Glasgow, UK.
  • Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.

Förderung

  • Janssen Global Services, LLC

Zitieren

APA

Fan, F., Davis, S., Burbridge, C., Chin, K., Friberg, M., Grünig, E., Hughes, M., Jansa, P., Linder, J., Rafalski, J., Rodriguez, A. A., & Randall, J. A. (2025). Single-Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A DUE Phase 3 Trial. Advances in Therapy. https://doi.org/10.1007/s12325-025-03159-x

Vancouver

Fan F, Davis S, Burbridge C, Chin K, Friberg M, Grünig E, et al. Single-Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A DUE Phase 3 Trial. Advances in Therapy. 2025. doi:10.1007/s12325-025-03159-x

BibTeX
@article{Fan2025,
  author = {Fan, Fenling and Davis, Stacy and Burbridge, Claire and Chin, Kelly and Friberg, Michael and Grünig, Ekkehard and Hughes, Melanie and Jansa, Pavel and Linder, Jörg and Rafalski, Jennifer and Rodriguez, Alvaro Agustin and Randall, Jason A},
  title = {Single-Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A DUE Phase 3 Trial},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-025-03159-x}
}
Kostenlos starten →